Director, US Lung Market Research
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
Reporting to the Executive Director, US Lung Analytics & Insights, the Director, US Lung Market Research will serve as the US Market Research lead for Revolution Medicines’ Lung cancer portfolio.
This role will partner closely with US Commercial, US Market Access, Global Insights, Medical Affairs, Clinical Development, and Business Operations to generate actionable insights that inform portfolio strategy, launch readiness, commercialization planning, and business performance.
